NYKODE-THERAPEUTICS
23.11.2021 07:02:07 CET | Business Wire | Press release
Nykode Therapeutics (formerly Vaccibody*) ) (Euronext Growth (Oslo): VACC (ticker will soon be changed)), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced today that the Company is changing its name to reflect its exciting development and mark a milestone in our journey of growth and transformation. It acts as a visible symbol of a new phase of opportunity based on collaborations, internationalization, and future ambitions. And it conveys how we are truly starting to realize our vision of being a leading immunotherapy platform company, breaking down the boundaries of conventional drug design to unlock the future of medicine.
The Company’s new name is inspired by its Norwegian roots and links to our platform’s modularity. Nykode translates as ‘new code’, playing on the potential of our technology to generate novel codes and create innovative patient therapies.
Michael Engsig, CEO of Nykode Therapeutics: “Over the last few years, the Company has made significant steps forward. We have reported promising clinical data, continued to grow our pipeline and forged significant partnerships.” Michael Engsig added, “We continue our exciting transformation from a two-asset focused company to a fully-fledged platform biotech company. During the past year, we have increased the number of talented colleagues, made important additions to our senior management team, invested strategically, and expanded internationally. This positive evolution, combined with our future ambitions, inspired the need to revisit our brand.”
Agnete B. Fredriksen, Chief Innovation & Strategy Officer of Nykode Therapeutics, continued, “The challenge of changing our name was to consolidate everything we have achieved to date with our future plans to expand, and combine this into a powerful new brand.” Agnete B. Fredriksen added, “We have shown that we can generate novel molecules by combining multiple different genes or codes to generate new medicines with unique properties. We will build further on this know-how, driven by our guiding purpose to push the boundaries of human advancement by rethinking conventional drug design. We want to express how our platform’s intelligent modular design and tailored hyper targeting may deliver game-changing medicines for patients. This vision aims to create innovative therapies and continues to broaden our reach into multiple therapeutic areas, both with and without our partners. In essence, we believe that our new name, Nykode, uniquely captures our progress and possibilities.”
Read more about the journey and inspiration regarding our new name, logo, and visual identity on our new website, nykode.com.
*) Vaccibody AS, which is changing its company name to Nykode Therapeutics AS, has called for an EGM on November 30, 2021, to vote for the approval of the change of its company name from Vaccibody AS to Nykode Therapeutics AS.
About Nykode Therapeutics
Nykode Therapeutics, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment cancer and infectious diseases. Nykode Therapeutics’ modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and elicit efficacious clinical responses.
Its lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies which is in Phase 2 for the treatment of cervical cancer; and VB10.NEO, a cancer neoantigen vaccine, which is exclusively out licensed to Genentech and is in Phase 1b for the treatment of locally advanced and metastatic tumours and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Nykode Therapeutics has initiated a Phase 1/2 trial in 2021 with its two next-generation COVID-19 vaccine candidates.
The Company has collaborations with Roche, Genentech and Nektar Therapeutics within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and collaborate with Adaptive Biotechnologies for COVID-19 T cell vaccine development.
Nykode Therapeutics’ shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is VACC (ticker will soon be changed). Further information about Nykode Therapeutics may be found at http://www.nykode.com
Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006744/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Interactive Brokers Launches Access to Korean Equities, Breaking New Ground for Global Investors7.5.2026 03:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of access to equities listed on the Korea Exchange (KRX), becoming the first major US-based broker to offer seamless trading in Korea's $1.8 trillion equity market. Korea ranks fourth among Asia's equity markets and tenth globally by market capitalization, with over $10 billion in daily volume – liquidity comparable to many European exchanges. The market is home to category-leading semiconductor manufacturers, automotive innovators, and consumer technology companies with global footprints, including Samsung Electronics, SK Hynix, and Hyundai Motor. As one of Asia’s most liquid markets, Korea represents a point of entry for international investors seeking exposure to the region’s technology leadership and industrial innovation. For investors operating across multiple markets and time zones, Interactive Brokers' launch expands the ability to build truly global portfolios with the same integrated tr
Andersen Global udvider med samarbejdspartneren NetExpat7.5.2026 01:38:00 CEST | Pressemeddelelse
Andersen Global styrker sin platform på tværs af Asien-Stillehavsområdet, Europa og USA gennem en samarbejdsaftale med NetExpat, der er en virksomhed med speciale i medarbejderassistance, interkulturel oplæring og ledelsesudvikling for internationalt mobile medarbejdere. NetExpat blev grundlagt for mere end 25 år siden og er en anerkendt markedsleder inden for global mobilitet og talentudvikling med støtte til multinationale kunder verden over. Virksomheden tilbyder vurderings-, trænings- og coachingprogrammer, der er designet til at understøtte globale arbejdsstyrker og deres medarbejdere i forbindelse med flytninger, herunder interkulturelle parathedsvurderinger, målrettet, effektiv kulturoplæring, karriere- og integrationsstøtte til medarbejderes ægtefæller samt talentudviklingsprogrammer for internationalt orienterede teams. "I mere end to årtier har NetExpat haft fokus på at hjælpe organisationer og deres medarbejdere med at trives med international mobilitet," udtaler Alain Verst
Brightfin Launches Spend Clearly AI to Help Enterprise Tech Leaders Take Control of Growing IT and AI Costs6.5.2026 22:32:00 CEST | Press release
New AI-powered optimization app delivers real-time visibility, cost reduction, and predictive forecasting as enterprise AI spending accelerates Brightfin, a leader in AI native IT cost optimization, today announced the launch of Spend Clearly AI, an intelligent optimization app purpose-built for enterprise technology leaders navigating the dual pressures of rising IT complexity and rapidly escalating AI investment. As organizations race to deploy AI apps, models, and infrastructure, technology demands on the budget are expanding faster than ever and growing harder to track, justify, and control. The modern enterprise IT bill has become a moving target. Spend Clearly AI gives CIOs, CTOs, and IT finance teams a single, intelligent app to see exactly where every technology dollar is going, eliminate waste, and stay ahead of costs before they spiral. "Stop thinking about IT as a cost problem. The goal isn't just to spend less — the goal is to spend better," said Joel Martins, CEO of Bright
iQmetrix to Showcase Intelligent Commerce Operating System and Catalyst Innovation at DTW Ignite 20266.5.2026 19:20:00 CEST | Press release
Bronze sponsor debut includes Catalyst project innovation, live platform demo, and a unified AI‑native commerce vision iQmetrix, the Intelligent Commerce Operating System for telecom, announced today it will exhibit, speak, and compete as a bronze sponsor at DTW Ignite 2026 in Copenhagen from June 23–25. The company will deliver a live product demo in The Loft, showcase its ODA PRISM Catalyst project alongside a consortium of global operators and technology partners, and exhibit at Booth #317 throughout the event. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506948390/en/ The debut marks a milestone in iQmetrix’s global growth strategy and deepens its partnership with TM Forum, following its recent recognition as an ODA Component Directory Partner. The Future of Commerce Is Won at the Orchestration Layer DTW Ignite 2026’s theme, “The Future. Faster.,” captures the urgency facing communications service providers worldwid
Go Beyond the Guidebook: Why Ireland Rewards Those Who Slow Down6.5.2026 18:15:00 CEST | Press release
In a world where travel often feels rushed and driven by checklists, Ireland stands apart. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501313521/en/ Lusty Beg Island Kesh, Co. Fermanagh The destination offers something deeper, drawing visitors beyond the expected toward richer encounters with its landscapes, culture and communities. As a compact island, Ireland gives holiday makers the chance to take in much of the destination while still travelling at a relaxed, unhurried pace. It’s a chance to slow down, not to do less, but to feel more - more calm, more connection, and more of what makes travel meaningful. This approach to travel is matched by Ireland’s natural warmth and welcome, helping visitors feel at home from the moment they arrive. Take the scenic route From the rugged coastline of the Wild Atlantic Way, one of the world’s longest coastal routes, to the rolling landscapes of Ireland’s Hidden Heartlands, Irela
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom